![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used to fund the clinical development of the company's lead product Tonmya (cyclobenzaprine HCl). Currently, it is being evaluated for treating patients with fibromyalgia.
Lead Product(s): Cyclobenzaprine
Therapeutic Area: Musculoskeletal Product Name: Tonmya
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dawson James Securities
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 13, 2024
Details:
The net proceeds will be used to fund the clinical development of the company's lead product Tonmya (cyclobenzaprine HCl). Currently, it is being evaluated for treating patients with fibromyalgia.
Lead Product(s): Cyclobenzaprine
Therapeutic Area: Musculoskeletal Product Name: Tonmya
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dawson James Securities, Inc
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 12, 2024
Details:
TNX-2900 (oxytocin) is a proprietary magnesium (Mg2+)-potentiated formulation of intranasal oxytocin. It is being evaluated for the treatment of Prader-Willi syndrome (PWS) in children and adolescents.
Lead Product(s): Magnesium Potentiated Oxytocin
Therapeutic Area: Genetic Disease Product Name: TNX-2900
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2024
Details:
The agreement aims for the potential launch and commercialization of Tonmya (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets), a centrally acting, non-opioid medication, in the US.
Lead Product(s): Cyclobenzaprine
Therapeutic Area: Musculoskeletal Product Name: Tonmya
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Almac Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 20, 2024
Details:
Tonmya (cyclobenzaprine HCl) is a sublingual product candidate. It is a multifuntional agent with antagonist activity at serotonin2A, α1-adrenergic, histaminergic-H1, and muscarinic-M1 receptors. It is being evaluated for the treatment of fibromyalgia.
Lead Product(s): Cyclobenzaprine
Therapeutic Area: Musculoskeletal Product Name: Tonmya
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
TNX-1500 is a Fc-modified humanized anti-CD40L monoclonal antibody that interacts with the CD40-ligand, which is being evaluated for the treatment of organ transplant rejection.
Lead Product(s): TNX-1500
Therapeutic Area: Immunology Product Name: TNX-1500
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
TNX-1500 is a Fc-modified humanized anti-CD40L monoclonal antibody that interacts with the CD40-ligand, which is being evaluated for the treatment of organ transplant rejection.
Lead Product(s): TNX-1500
Therapeutic Area: Immunology Product Name: TNX-1500
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2024
Details:
Tonmya (cyclobenzaprine HCl) is a sublingual product candidate. It is a multifuntional agent with antagonist activity at serotonin2A, α1-adrenergic, histaminergic-H1, and muscarinic-M1 receptors. It is being evaluated for the treatment of fibromyalgia.
Lead Product(s): Cyclobenzaprine
Therapeutic Area: Musculoskeletal Product Name: Tonmya
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
The collaboration aims to support Tonix to focus on the Tonmya (cyclobenzaprine HCl), which is a multifunctional agent with potent binding and antagonist activity at the 5-HT2A-serotonergic. It is in development as a daily bedtime treatment for fibromyalgia.
Lead Product(s): Cyclobenzaprine
Therapeutic Area: Musculoskeletal Product Name: Tonmya
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Rho
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 13, 2024
Details:
Tonmya (TNX-102 SL) is a sublingual tablet formulation of cyclobenzaprine hydrochloride, which is being evaluated for the treatment of acute stress disorder (ASD) and posttraumatic stress disorder (PTSD).
Lead Product(s): Cyclobenzaprine
Therapeutic Area: Psychiatry/Psychology Product Name: Tonmya
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024